Side-by-side · Research reference
P21vsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BHuman-MechanisticAUTO-DRAFTED12/36 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
P21
Pinealon
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
—
—
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Pinealon
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Russian clinical trials + in vitroKhavinson 2014
Duration
Not specified
10-day cycles, 1–2× per year
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Frequency
—
Once daily during cycle
Lower / starter dose
—
2.5 mg / day
Reconstitution
—
Bacteriostatic water
Timing
—
No specific time
Half-life
—
Hours
04Side Effects & Safety
Parameter
P21
Pinealon
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Injection site reaction
—
Mild irritation
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
P21
- ·Use in humans not validated
Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
P21
Pinealon
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
SQ — abdomen preferred.
3. Timing
—
Daily during cycle, any time.
4. Storage
—
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
P21
— no documented stacks
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation